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CR, SK) and insurance records (HU). Direct costs from the payer’s perspective were
based on published national sources (CR, SK), DRG lists (PL) and the insurance
records (HU). RESULTS: The incidence of hospitalized bacteraemia/sepsis and
meningitis per 100,000 person years were: 2.07 and 1.34 (CR), 1.2 and 0.49 (SK), 0.66
and 0.32 (PL), and 3.16 and 1.01 (HU). The case fatality rate was: 31% and 25%, 12%
and 25%, 40% and 63%, and 11% and 29%. An exponential increase in both measures
was apparent with advancing age. The total economic burden of IPD in adults over
50 was: EUR 666,050; 159,528; 180,015 and 140,249. Adults 65, who represent 41%
of the combined population, account for 54% of the costs. CONCLUSIONS: The IPD
burden in adults increases with age, and is associated with a high risk of death.
Higher incidence in HU obtained from insurance records seems to more reliably
reflect the reality and highlights systematic underreporting of national surveil-
lance systems.
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OBJECTIVES: To estimate the stroke related disease burden in terms of health care
resource utilization and average per-patient costs among patients with a prior
diagnosis of non-valvular atrial fibrillation (NVAF) in India. METHODS: Data were
collected retrospectively in three large multidisciplinary community hospitals in
three cities in India. Medical charts of 400 patients diagnosed with stroke and NVAF
from June 1, 2011 to September 1, 2011 were reviewed. Data abstracted were demo-
graphic characteristics, clinical diagnosis, risk factors, comorbid conditions, date of
diagnosis/admission, date of discharge, and types of inpatient procedures. Data
regarding outpatient services such as physician visits, laboratory tests, INR moni-
toring, diagnostic tests, nursing services, and speech/physiotherapy over a three
month period post-discharge were obtained via patient follow-up surveys. Costs
associated with inpatient services were obtained from hospital discharge bills and
the pricing menu of the three hospitals. RESULTS: The mean age of patients in the
study was 59 (SD 10) and the majority of patients (62%) were male. Of the 400
patients, 61% had ischemic stroke and about 60% of the patients were moderate to
moderate-severe disabled based on the modified Rankin Scale. The mean length of
stay for patients with ischemic stroke was 16 days (SD 4). The direct medical costs
for patients with moderate or more severe ischemic stroke (inpatient and outpa-
tient) over the 3 month follow-up period was Indian rupees, Rs 130,976 (SD 3,913)
with inpatient hospital costs accounting for a major portion (Rs 114,202) of the
overall costs (per patient). CONCLUSIONS: The findings of the study indicated that
the acute treatment for 3 months post ischemic stroke among NVAF patients im-
poses considerable economic burden (US $7,138) among patients in India. As inpa-
tient costs are major cost drivers, clinical efforts should focus on timely manage-
ment of NVAF induced strokes and use of preventive treatments.
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OBJECTIVES:To calculate the health care cost of traffic accidents occurring in night
or daylight under low visibility. METHODS: Data on traffic accidents derive from
the database of Hungarian Central Statistical Office (HCSO). We assessed the cost of
both health services in kind and health services in cash. The direct cost related to
traffic accidents were derived from the financial database of the National Health
Insurance Fund Administration, the only health care financing agency in Hungary
(Hungarian DRG point system version 5.0). Cost of benefits in cash was calculated
with an average sick pay. The average recovery period of patients with traffic
accidents was assumed 4 months. RESULTS: A total of 20635 persons were injured
and 1106 persons were died on the road by traffic accident. 45 percent of casualty
has been taken in night or daylight under low visibility. Average cost of restricted
visibility accidents is 510886 HUF per capita (approx. 2041 EURO). We calculated an
average sick pay 119365 HUF (approx. 477 Euro) per capita per month. The expen-
ditures of the National Health Insurance Fund Administration could easily reach
the 17 billion HUF (approx. 67.9 million Euro) per years. CONCLUSIONS: Traffic
accidents and subsequent medical conditions are important burden for the Hun-
garian health insurance system with an annual expenditure of 17 billion HUF (97,9
million EURO). Better illumination, law regulation, appropriate education and traf-
fic instructions might decrease the costs related to accidents on the road.
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OBJECTIVES: Gastrointestinal bleeding is one of the most common causes of med-
ical attention in-hospital demand, with high impact on morbidity, mortality and
costs of care. The aim of this study was to evaluate from the public payer perspec-
tive in Mexico, the cost of care of patients with gastrointestinal bleeding.
METHODS: Through review of medical records of patients with gastrointestinal
bleeding from January to March 2012 in a hospital in the Mexican Social Security
Institute (IMSS) we evaluated the length of hospital stay, laboratory tests, endos-
copy and pharmacological treatment prescribed. We used as reference the 2011
database of the institution and expressed the cost in U.S. dollars (USD) at an ex-
change rate of 13.72 Mexican pesos/USD [June 2012] and calculated the average cost
per patient, we identified the component of major cost and identify the factor
associated with higher cost. RESULTS:We included 70 patients with mean age 68
14 years, 61% were women. 80% of cases had a comorbidity, the most frequent was
systemic arterial hypertension (90%). On average hospital stay was 8 4 days. The
average cost per patient was 3.776 USD (1.490 USD- 8.180). The major cost compo-
nent was hospital stay accounting for 81% of total costs. In patients Age over 85
years, the presence of comorbidities or gender were no associated with higher cost
(p 0.05). CONCLUSIONS: Gastrointestinal bleeding is a major cause of resource
utilization for the IMSS, the main component are the days of hospital stay which
cause a high economic impact on accessibility to other hospital claims.
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OBJECTIVES: In France, 4-10% of the population is annually affected by influenza.
This represents direct and indirect costs, which vary according to the dominant
influenza virus strain circulating. Policy makers are interested in its burden, for
better allocating resources for prevention and control measures. As international
literature regarding seasonal influenza B is rare and not entirely applicable in
France, our study aims to assess its costs in 2010/2011 under the French Health
Insurance perspective. METHODS: Cases: patients of all ages, consulting for an
acute respiratory infection a physician, member of an influenza surveillance net-
work in France (GROG network), completing the routine clinical form and whose
nasopharyngeal swab was lab confirmed positive for influenza B. Physicians com-
pleted follow-up questionnaires 7 and 28 days after swabbing. Costs (consults,
drugs, exams, hospitalization and daily allowances) were assessed for each pa-
tient. Treatments costs were modelled using linear, tobit and probit regressions
(variables: costs, risk factor, vaccination, age group). Total costs estimation for the
French Health Insurance were calculated by multiplying total costs per patient, flu
attack rate and population. RESULTS: N201 patients were included. Influenza B
mean cost was 90.63€ (SD 132.76) per patient. Risk factors or influenza vaccine
status did not impact the mean cost. In children and older people these costs were
very similar (0-4 yo76.74€, 5-14 yo75.45€, 65 yo72.50€). Main cost items were
follow-up consults and antibiotics. For adults, costs almost doubled, reaching ap-
proximately 141.25€ per patient, due to work absenteeism. Total influenza B costs
for the National Health Insurance were estimated on almost 400 million Euros in
France during 2010/11. CONCLUSIONS: The results show that in a season where
influenza B is dominant, it causes an important economic impact. Further investi-
gations of strategies (vaccines) for reducing influenza B cases, providing evidence
for policy-makers’ decisions are in progress.
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OBJECTIVES: To assess the clinical and demographic characteristics, utilization,
and cost patterns of human immunodeficiency virus (HIV) patients in the U.S.
veteran population. METHODS: A retrospective analysis was performed using the
Veterans Health Administration (VHA) Medical SAS Datasets from October 1, 2007
to September 30, 2011. All U.S. veteran beneficiaries diagnosed with HIV were iden-
tified using International Classification of Disease 9th Revision Clinical Modifica-
tion (ICD-9-CM) diagnosis codes 042.xx and V08.xx. Descriptive statistics were cal-
culated as means  standard deviation (SD) and percentages to measure
demographic, cost, and utilization distribution in the sample. RESULTS: A total of
2,432 patients were diagnosed with HIV, who were most frequently designated as
Caucasian (n1,201, 49.38%) and often lived in the southern parts of the United
States (n905, 37.21%). Common comorbidities included hypertension (n1,531,
55.55%) and diabetes (n558, 22.94%). Survival rates were high for all age groups
(age 39: 98.21%; 40-64 years: 93.48%; 65: 87.11%). Outpatient services were uti-
lized by 99.92% of HIV patients, followed by inpatient (20.44%) and outpatient emer-
gency room (ER) visits (7.11%). An average number of 0.39 inpatient visits and 21.01
outpatient visits per patient occurred during the 1-year follow-up period. Outpa-
tient office ($10,558, SD$12,856), outpatient ER ($36, SD$240), and inpatient
($8,371, SD$35,444) values contributed to follow-up health care expenditures.
CONCLUSIONS: U.S. veterans with HIV experienced a high average number of
outpatient visits during the follow-up period as well as frequent comorbidities and
high survival rates. These may have translated to the high outpatient expenses
evident in the study.
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OBJECTIVES:The management of atrial fibrillation (AF) represents a significant and
increasing burden on the UK National Health Service (NHS). Understanding this
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burden is important in informing health care planning and policy development.
This study was conducted to describe the NHS costs associated with AF manage-
ment in routine UK clinical practice. METHODS: A retrospective observational
study of 825 patients with AF was undertaken in 8 UK primary care practices in
2010. Data were collected from the clinical records of all eligible, consenting pa-
tients, for a period of up to 3 years. The first 12 weeks following diagnosis was
defined as the ‘initiation phase’; the period after week 12 was defined as the ‘main-
tenance phase’.RESULTS:Mean (SD) total cost of AF management was £947/€1,153/
1,476USD (£1,098/€1,337/$1,711) per patient in the initiation phase and £469/€571/
$731 (£597/€727/$930) per patient year in the maintenance phase. Inpatient
admissions and secondary care attendances accounted for 83% of total initiation
phase and 64% of total maintenance phase costs. Significant variables contributing
to high cost in the initiation phase were co-morbid hypertension and lower patient
age, although only accounting for 5% of cost variability. Significant variables in the
maintenance phase (18% of cost variability) were co-morbid congestive or struc-
tural heart disease and diabetes, and day-care attendances, ECGs and hospitalisa-
tions in the initiation phase. Mean maintenance phase costs were higher for pa-
tients managed by practices providing anticoagulation services (£555/€676/$865)
than patients receiving secondary care anticoagulation (£421/€513/$656, p0.002).
CONCLUSIONS: The study confirms that inpatient admissions and secondary care
attendances contribute most to total AF management costs. None of the variables
analysed accounted for much variability in the total cost of AF management, sug-
gesting that it is often not possible to predict which patients will be high NHS
resource users. Future work should focus on how to safely reduce avoidable hos-
pital admissions.
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OBJECTIVES: Studies estimating the cost of treating patients suffering from the
Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) have not been conducted
in Greece. The aim of this study was to investigate the annual cost of patients with
OSAHS and identify the potential economic burden to the patients treated.
METHODS: A retrospective study was conducted in the sleep laboratory of Sotiria
Chest Hospital in Athens from January 1, 2008 to December 31, 2008. A sample of
340 subjects was screened for OSAHS. Diagnosis was confirmed after polysomnog-
raphy. Health resources’ consumption was derived from patients’ analytical re-
cords, the annual visits in the sleep laboratory and the purchase of the ventilation
devices (CPAP, BiPAP). Outpatient visits’ costs included labor costs, overheads, con-
sumables related to the OSAHS patients. The bottom-up approach and the pa-
tients’ perspective have been used. RESULTS: A total of 262 males and 78 females,
mean aged 55,9 (SD12,4) years participated in this study. Overall mean annual
cost reaches approximately €1.685,90 per patient out of which 15% is paid by NHS,
64% by social funds and 21% by patients’ out-of-pocket payments. The major cost
driver is devices’ purchase (66.55%). Patients’ out of pocket spending for the pur-
chase of the BiPAP ranges from 5% to 48.6% and of the CPAP from 0% to 33.5%
depending on the social fund in which the patient belongs. CONCLUSIONS: Varia-
tions are found among patients’ social insurance coverage related to the purchase
of both devices as well as severe inequalities in patients’ cost sharing among the
various funds. Further research is needed in similar sleep laboratories in Greece.
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OBJECTIVES: To describe health care costs associated with the management of PsA
in patients newly initiated on a biologic DMARD or MTX.METHODS:Adult patients
with 2 PsA diagnosis (from office visits), continuously enrolled 6-month pre-
and12-month post-index date (i.e., first biologic DMARD/MTX prescription date),
and no diagnosis for ankylosing spondylitis were selected from the MarketScan
Commercial Claims database (2005-2009). MTX initiators were required to be both
biologic and non-biologic DMARD naïve prior to index date. Biologic initiators were
required to be biologic-naïve only prior to index date. All-cause and PsA-related
total health care costs were estimated during the 12-month study period from a
payer perspective (2011 USD). PsA-related medical cost was defined as costs asso-
ciated with a claim with a PsA diagnosis or with DMARD administration by health
care professionals. Office care and monitoring costs were defined as the sum of
PsA-related outpatient and other medical services costs (excluding costs for drugs
administration). Urgent care costs were defined as the sum of inpatient and emer-
gency room costs. PsA-related pharmacy costs were defined as the sum of biologic
and non-biologic DMARD costs. RESULTS: A total of 1,217 MTX initiators and 3,263
biologic initiators met the eligibility criteria. MTX initiators had an average annual
total health care cost of $14,329 where $6,065 were PsA-related. Pharmacy costs
accounted for 80.4% of total PsA-related costs; office care and monitoring costs for
16.3%; urgent care costs for 3.3%. Biologic initiators had an average annual total
health care cost of $30,282 and 67.5% were PsA-related. Pharmacy costs accounted
for 92.7% of PsA-related total costs; office care and monitoring cost for 5.1%; urgent
care cost for 2.3%. CONCLUSIONS: PsA patients initiating a DMARD incurred sub-
stantial health care costs. Although pharmacy costs accounted for most of the
PsA-related costs, office care and monitoring costs represented a significant part of
the PsA-related costs.
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OBJECTIVES: To evaluate the most frequent outpatient care physiotherapy ser-
vices provided for musculoskeletal and connective tissue diseases and determine
the total health care expenses of them. METHODS: Data were derived from the
countrywide database of Hungarian Health Insurance Administration (HHIA),
based on official reports of outpatient care institutes in 2008. The total numbers of
different physiotherapy services were determined by selecting the reported spe-
cific diagnoses codes and counting the number treatments provided for that spe-
cific diagnosis code. The different types of treatment codes are listed in the chapter
of the Guidelines of HHIA for ‘Physiotherapists, massage-therapists, conductors
and other physiotherapy practices‘. The musculoskeletal and connective tissue
diseases are listed in the International Classification of Diseases (ICD) with code of
M00-M99. RESULTS: The total number of the 151 different types WHO-classified
physiotherapy services was 29045736 in the year of 2008, 17455468 (60.1%) of them
with the ICD code group M00-M99. The services with highest incidence are the
followings: 1) ultrasound therapy 2011189 (11.52%); 2.) iontophoresis 1586016
(9.08%); 3) massage therapy with hand l946364 (5.42%); 4) middle frequency elec-
trotherapy 932474 (5.34%); and 5) passive motion therapy on multiple limbs 821314
(4.7%). The number of the 20 most frequent types of therapies was 14285957, which
is the 81.84% of all cases. The total health insurance reimbursement of the treat-
ments of diseases with ICD code M00-M99 was 4.713 billion Hungarian Forint (18.76
million EUR). CONCLUSIONS: The 60.1% of the total number of physiotherapy ser-
vices were provided for the treatments of diseases with ICD code M00-M99, sup-
porting the notion that physiotherapy is dominantly used in the treatment mus-
culoskeletal diseases. The financial cost of the outpatient care physiotherapy of
diseases with ICD code M00-M99 exceeded the 50% of the total budget provided for
physiotherapy services.
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OBJECTIVES: To evaluate the most frequent outpatient care physiotherapy ser-
vices provided for trauma patients and determine the total health care expenses of
them. METHODS: Data were derived from the countrywide database of Hungarian
Health Insurance Administration (HHIA), based on official reports of outpatient
care institutes in 2008. The total numbers of different physiotherapy services were
determined by selecting the reported specific diagnoses codes and counting the
number treatments provided for that specific diagnosis code. The different types of
treatment codes are listed in the chapter of the Guidelines of HHIA for ‘Physiother-
apists, massage-therapists, conductors and other physiotherapy practices’. The
injuries caused by trauma are listed among with all type of injuries, poisoning and
other external mechanisms in the International Classification of Diseases (ICD)
code group of S00-T98. RESULTS: The total number of the 151 different types WHO-
classified physiotherapy services was 29045736 in the year of 2008; 3188650 of them
with the ICD code group S00-S99. The services with the highest incidence are the
followings: 1) individual physiotherapy 352406 (11.15%), 2) muscle strengthening
exercises 251398 (7.88%), 3) stretching of contractures 247442 (7.76%), 4. circulation
enhancing physiotherapy 230930 (7.24%) and 5) exercises against resistance 210703
(6.61%). Of all body regions, the knee and the lower leg demanded the highest
number of treatments (22.4%), followed with the shoulder (22.31%), elbow (18.7%)
and wrist (14.18%); while the lowest number of services was required after the head
(1.71%) and neck (0.67%) traumas. The total health insurance reimbursement of
diseases with ICD code S00-S99 was 962 million Hungarian Forint (3.829 million
EUR). CONCLUSIONS: The number of treatments accompanied diseases with ICD
code S00-S99 in the year of 2008 shows a relatively low percentage (11%) of all
physiotherapy services.
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OBJECTIVES: End stage renal failure is expected to become a major health problem
for Turkey due to aging population and the increasing incidence of chronic diseases
with renal effects. It was reported that end stage renal failure incidence with a need
for transplantation has risen from 350 to 847 per million population from 1998 to
2009. In addition, the number of patients needing dialysis treatment has also risen
from 3069 to 46659 for the same years. Dialysis treatment is predominantly in
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